B1 BREAKFAST WORKSHOP
Organised by Vital Transformation, US Chamber of Commerce and Pfizer
This breakfast session will offer an open debate on the role of IP in EU healthcare innovation, focused on the appropriate role and balance for both public funding and private investments, supported by new research on EU biotech success factors produced by Vital Transformation. Speakers will discuss in a pro-con format whether IP is a problem or a solution to our healthcare needs, and what role the EU will play in supporting next-generation health technologies to promote a sustainable R&D infrastructure in Europe.
Many healthcare regulators and payers feel that new medicines which were developed using public funding should be made available for free, and that private ownership of products which used public funds is impacting the sustainability of the EU healthcare system. Others, such as state pension funds, industry, and investors feel strongly that private funding is what drives the success and growth of new healthcare technologies, and removing the private ownership of healthcare products will radically impact the sector negatively. We aim to test both hypothesis in this open discussion.
Topics will include:
• The role of public and private funding in developing new health technologies
• The drivers of success that impact high-growth biotech companies
• The current gap emerging between EU, US, and Chinese IP productivity in healthcare
• The current international debate on pricing and IP in the bio-pharmaceutical sector
EVA GRUT-AANDAHL, Vice President, Head of European Government Affairs, Pfizer
EMIL POT, European patent attorney, NLO
YANNIS NATSIS, Policy Manager for Universal Access & Affordable Medicines, European Public Health Alliance
NICOLA BEDLINGTON, Secretary General, European Patients‘ Forum
DUANE SCHULTHESS, Managing Director, Vital Transformation